abstract |
The present invention provides an induced pluripotent stem (iPS) cell, or population of iPS cells, wherein the cell or cells giving rise to the iPS cell(s) are obtained from human postpartum tissue or cells, wherein the iPS cell(s) have increased levels of one or more factors selected from Group I: an Oct family member, a Sox family member, a Klf family member, a Myc family member, Nanog, Lin28, and combinations thereof. The present invention also provides differentiated cells derived from the cells of the invention and compositions, including pharmaceutical compositions comprising the cells of the invention. The invention further provides uses of the cells of the invention, e.g., in the treatment of a subject suffering from a disease of disorder. The invention additionally provides methods of generating iPS cell(s) from postpartum tissue, such as the cells of the invention. |